Literature DB >> 10354862

In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

R Patel1, M S Rouse, K E Piper, J M Steckelberg.   

Abstract

We report the activity of the new oxazolidinone antimicrobial agent linezolid against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 20 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci were inhibited by < or = 4 ug/ml of linezolid. All isolates of methicillin-resistant S. aureus were inhibited by < or = 8 ug/ml of linezolid. All isolates of penicillin-resistant S. pneumoniae were inhibited by < or = 2 ug/ml of linezolid. Linezolid inhibits strains of multidrug resistant Gram-positive cocci in vitro at concentrations < or = 8 ug/ml.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10354862     DOI： 10.1016/s0732-8893(99)00016-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  16 in total

1.  Staphylococcus aureus Endocarditis in the 21st Century.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.

Authors:  R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 4.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Clinical experience with linezolid in the treatment of resistant gram-positive infections.

Authors:  S J Antony; E Diaz-Vasquez; C Stratton
Journal:  J Natl Med Assoc       Date:  2001-10       Impact factor: 1.798

6.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.

Authors:  E-M Klupp; A Both; C Belmar Campos; H Büttner; C König; M Christopeit; M Christner; M Aepfelbacher; H Rohde
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-15       Impact factor: 3.267

Review 8.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.

Authors:  Nuggehally R Srinivas; Muzeeb Syed
Journal:  Drugs R D       Date:  2016-03

10.  Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Raymond Cha; William J Brown; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.